SRR1335446
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.517
- INFLAMMATORY_RESPONSE+0.497
- IL6_JAK_STAT3_SIGNALING+0.480
- ANGIOGENESIS+0.448
- TNFA_SIGNALING_VIA_NFKB+0.444
- INTERFERON_GAMMA_RESPONSE+0.429
- INTERFERON_ALPHA_RESPONSE+0.369
- KRAS_SIGNALING_UP+0.343
- COAGULATION+0.321
- COMPLEMENT+0.321
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.624
- ADIPOGENESIS-0.483
- MYC_TARGETS_V1-0.475
- DNA_REPAIR-0.474
- MYC_TARGETS_V2-0.466
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.427
- FATTY_ACID_METABOLISM-0.418
- PROTEIN_SECRETION-0.402
- MITOTIC_SPINDLE-0.382
- PEROXISOME-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607445 | GTEX | — | 0.975 |
| 2 | SRR1358561 | GTEX | — | 0.960 |
| 3 | SRR599510 | GTEX | — | 0.958 |
| 4 | SRR608598 | GTEX | — | 0.956 |
| 5 | SRR1474795 | GTEX | — | 0.955 |
| 6 | SRR821602 | GTEX | — | 0.952 |
| 7 | SRR1077405 | GTEX | — | 0.944 |
| 8 | SRR602131 | GTEX | — | 0.943 |
| 9 | SRR603658 | GTEX | — | 0.941 |
| 10 | SRR1467294 | GTEX | — | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.517 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.497 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.448 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.444 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.429 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.369 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.343 | Inavolisib | — uncovered |
| COAGULATION | 0.321 | Binimetinib | — uncovered |
| COMPLEMENT | 0.321 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.273 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.226 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.199 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.197 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.175 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.075 | Inavolisib | — uncovered |
| APOPTOSIS | 0.071 | Idelalisib | — uncovered |
| HYPOXIA | 0.024 | Idelalisib | — uncovered |